FATE vs MS · rev $13.6M vs P/E 20, $344.27B cap
Fate Therapeutics Inc (FATE) versus Morgan Stanley (MS) — a side-by-side from cached financials, not a winner call.
Fate Therapeutics Inc (FATE) is a biotechnology company listed on US.
Morgan Stanley (MS) is a capital markets company listed on US. It is led by Ted Pick.
Latest reported FATE revenue for 2024-12-31 was $13.6M. Net income was -$186.3M. Revenue was down 78.5% from 2023-12-31 to 2024-12-31. FATE currently screens at market cap $331.0M.
MS does not have a complete income-statement cache yet.
FATE currently screens at market cap $331.0M. MS currently screens at market cap $344.27B and trailing P/E 19.8.
Not investment advice. Open the FATE and MS stock pages for the full models.
Not investment advice.